Oncothyreon Files Investigational New Drug Application for ONT-10

Oncothyreon Inc.

today announced the filing of an Investigational New Drug (

) application with the U.S. Food and Drug Administration for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1. Upon completion of the FDA's review of the IND, Oncothyreon expects to initiate a Phase 1 trial of ONT-10. "We are pleased to announce the filing of this IND, which is a significant milestone for our therapeutic vaccine development program," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "ONT-10 and its adjuvant component, PET-Lipid A, were internally discovered and developed and remain fully owned by Oncothyreon."